VSTM — Completion of ROCKIF Trial on Carboplatin-resistant Ovarian Cancer
Apr 1, 2026, 4:00:00 AM UTC
Summary
The ROCKIF trial, investigating the efficacy of VS-6063 in combination with carboplatin and paclitaxel for treating carboplatin-resistant ovarian cancer, is set for expected completion on April 1, 2026. Sponsored by Michael McHale at the University of California, San Diego, the trial is currently in the recruiting phase with an enrollment target of 90 patients. While carboplatin and paclitaxel are FDA-approved treatments, VS-6063 remains experimental. The study aims to assess both the safety of this therapeutic regimen and its potential to reduce cancerous cell levels in patients.
Company
VERASTEM INC (VSTM)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.verastem.comSimilar Events
Completion of STRO-002 Clinical Trial on Epithelial Ovarian Cancer
Tasly Pharmaceutical Group Co., Ltd. is nearing the completion of its clinical trial for STRO-002, a drug targeting epithelial ovarian cancer and other advanced malignant solid tumors in Chinese adults. The trial, marked by both Phase I (dose escalation) and Phase IIa (dose expansion), is set to conclude on December 30, 2027. The overall status of the trial is currently 'RECRUITING' with 132 subjects enrolled. Under the guidance of Tasly, this study represents important progress in cancer therapeutics for this patient population.
Clinical Trial CompletionExpected Completion of Clinical Trial for Ovarian Cancer - NCT05479045
The clinical trial NCT05479045, sponsored by Georgetown University, is set to complete on November 1, 2026. This study, which is not yet recruiting, aims to evaluate the efficacy of a combination therapy intended to prevent resistance to anti-PD-1 therapy in patients with platinum-refractory stage III/IV ovarian cancer. The trial involves 24 participants and is classified as a Phase II, open-label, non-randomized study. Investors should note the potential implications of this work on treatment options for metastatic ovarian cancer.
clinical trial completionNirogacestat in Ovarian Granulosa Cell Tumors Clinical Trial Completion
SpringWorks Therapeutics, Inc. expects to complete the clinical trial studying nirogacestat for the treatment of ovarian granulosa cell tumors (OvGCT) by December 1, 2027. OvGCTs represent a significant occurrence in ovarian cancers, affecting approximately 1,500 to 2,000 newly diagnosed patients annually in the U.S. The trial is designed as a single-arm Phase 2 study, assessing the efficacy, safety, and tolerability of nirogacestat, which is anticipated to inhibit Notch-induced proliferation of granulosa cells. A total of 53 participants are enrolled in an active, not recruiting status, continuing treatment until disease progression or unacceptable toxicity occurs. This study's outcomes could have implications for treatment options in a rare but challenging subset of ovarian cancer.
Clinical Trial CompletionCompletion of NCT04008030 Clinical Trial for Metastatic Colorectal Cancer
Bristol-Myers Squibb has completed the clinical trial NCT04008030, which compared nivolumab and nivolumab plus ipilimumab against standard chemotherapy in treating patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). The trial aimed to assess the clinical benefits in terms of progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) among the 1,147 enrolled participants. With a completion date set for June 10, 2026, the results may provide crucial insights into treatment efficacy for this patient population.
clinical trial completion